8-15 | Aquarius has received formal permission from the Maltese authorities to enter the port of Valletta. MSF is relieved that a place of safety has been found for the 141 vulnerable people rescued on the Mediterranean.
8-12 | Responding to the ongoing humanitarian crisis in the Central Mediterranean, a total of 141 people were rescued on Friday by the search and rescue vessel Aquarius, chartered by SOS MEDITERRANEE and operated in partnership with Médecins Sans Frontières (MSF).
Myanmar: Independent humanitarian agencies and access to health care still blocked in northern Rakhine
8-11 | Independent humanitarian agencies remain largely blocked from accessing vulnerable communities in northern Rakhine, raising major concerns about unmet medical and humanitarian needs, said Médecins Sans Frontières/Doctors Without Borders (MSF). On 11 August 2017, two weeks prior to attacks by the Arakan Rohingya Salvation Army (ARSA) and the Myanmar Army’s so-called “clearance operations” that followed, MSF lost government authorisation to carry out medical activities in northern Rakhine.
8-1 | The rescue boat Aquarius, run in partnership between SOS MEDITERRANEE and Médecins Sans Frontières (MSF), sets sail today from Marseille after an extended port call. Aquarius is heading back to the Central Mediterranean in order to render assistance to persons in distress at sea. “The Central Mediterranean route is the deadliest in the world,” said Aloys Vimard, MSF’s Project Coordinator on board the Aquarius. “There are hardly any rescue ships left in the Central Mediterranean and no dedicated search and rescue capacity from European states.
7-20 | RCEP trade deal could cut medicines lifeline for people in developing countries As the sixteen countries negotiating Regional Comprehensive Economic Partnership (RCEP) trade agreement meet in Bangkok this week for another round of closed door negotiations, public health experts and the international medical humanitarian organization - Médecins Sans Frontières (MSF) warn that inclusion of any harmful intellectual property provisions in the agreement could have a severely negative impact on access to affordable generic medicines.